Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services’s Eledon Pharmaceuticals ELDN Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$133K	Buy	+34,615	New	+$126K	﹤0.01%	3729

Other funds holding ELDN

Triumph Capital Management Denver, Colorado $552M AUM 20.75% 1-Year Est. Return

Prodigy Asset Management Omaha, Nebraska $332M AUM 10.57% 1-Year Est. Return

Howard Financial Services Dallas, Texas $1B AUM 20.02% 1-Year Est. Return

Relyea Zuckerberg Hanson Stamford, Connecticut $1.2B AUM 28.45% 1-Year Est. Return

Revolve Wealth Partners Hackensack, New Jersey $965M AUM 22.88% 1-Year Est. Return

GK Wealth Management Reno, Nevada $190M AUM 66.42% 1-Year Est. Return

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

Farmers & Merchants Investments Inc Lincoln, Nebraska $4.13B AUM 32.58% 1-Year Est. Return

SOA Wealth Advisors New York $595M AUM 25.98% 1-Year Est. Return

Wealth Enhancement Advisory Services's ELDN Position: Q2 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Eledon Pharmaceuticals (ELDN) in Q2 2026: 34,615 shares worth $133K. The stake represents ﹤0.01% of the portfolio and ranks #3729 among its holdings.

19 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

Wealth Enhancement Advisory Services held 34,615 shares of Eledon Pharmaceuticals worth $133K as of Q2 2026.
Eledon Pharmaceuticals was a new Wealth Enhancement Advisory Services position in Q2 2026.
Eledon Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3729 holding.
19 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.